A New Immuno-Resolving Treatment Paradigm for Inflammatory Bowel Disease (IBD)
IBD is a group of disorders characterized by inflammation and ulceration of the small and large intestines. The two major types of IBD are Ulcerative Colitis, which occurs in the colon and rectum, and Crohn’s Disease, which affects tissue throughout the intestinal tract.
Existing therapies for inflammatory bowel disease (IBD) work by blocking or inhibiting key steps in the inflammatory process. As a result, they can cause systemic immunosuppression potentially leading to undesirable side effects, along with increased risk of infection and malignancy. Moreover, up to 50% of patients treated with current therapies are non-responsive or experience relapse within 12 months of a prior flare. Thus, there is a clear need for additional therapeutic options.
Thetis is developing novel small molecule drugs for the treatment of IBD based on a paradigm of resolving inflammation. In contrast to existing therapies that work by inhibiting the inflammatory process, Thetis agents offer a fundamentally new immuno-resolving approach to IBD treatment based on promoting tissue repair and healing without suppressing normal immune function. Thetis agents deliver endogenous bioactive lipids that play a critical role in regulating the inflammatory immune response. Thetis achieves this through a proprietary technology platform that unlocks the potent pharmacology of these lipids as new molecular entities.
Thetis has two candidates in preclinical development. TP-252 is a unique derivative of eicosapentaenoic acid, which has been shown in an independent Phase 2 trial to be effective in treating ulcerative colitis. TP-252 is targeted as adjunct therapy over first-line 5-ASA therapy before escalation to more side-effect prone immune-suppressants and biologics. TP-317 is a unique derivative of a newly discovered class of bioactive lipids known as specialized pro-resolving mediators (SPMs). TP-317 has the potential to be a non-immunosuppressive alternative or complement to biologics for treatment of IBD.